BDR Pharma launches enzalutamide in 160 mg strength
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
As per union government, growing public participation reflects rising awareness and collective commitment towards advancing organ and tissue donation
Union Health Minister calls for heightened vigilance, stronger public awareness campaigns, and district-specific action plans for the high-transmission season
Leading experts from AIIMS Kalyani, Syngene, Veeda Lifesciences, Lambda Therapeutic, DNDi, JSS Medical, KIHT, InoRx, ISCR and SIRO Clintech to discuss India’s readiness as preferred clinical research destination
Robotic TAMIS procedure helps 75-year-old patient avoid rectum removal and permanent stoma, enabling faster recovery and preserving quality of life
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
Subscribe To Our Newsletter & Stay Updated